MD Anderson Cancer Center

The University of Texas

Houston, TX

Accepting patients

ELEMENT-MDS

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD)
Learn more
  • Erythroid Maturation Agent (EMA)
  • Erythropoiesis-Stimulating Agent (ESA)
  • Red Blood Cell Stimulant
  • Phase 3

Accepting patients

Personalized Natural Killer Cell Therapy

Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Azacitidine and Enasidenib for IDH-2 Mutations

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Learn more
  • IDH2 Inhibitor
  • Phase 2

Not yet accepting

Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
Learn more
  • Antisense Oligonucleotide (ASO)
  • BCL-2 Inhibitor
  • Phase 1

Accepting patients

Cladribine, Cytarabine and Venetoclax for HR-MDS

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2
  • Has results

Accepting patients

Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Learn more
  • JAK1 Inhibitor
  • Kinase Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2
  • Has results

Accepting patients

A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Natural Killer Cells (Allogeneic)
  • White Blood Cell Stimulant
  • Phase 1/2

Accepting patients

TakeAim

TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • IRAK 4 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1/2
  • Has results

Accepting patients

Venetoclax Plus Azacitidine

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Filters

Diagnosis

Purpose of Trial

MDS Centers of Excellence

Advanced Filters

Hide Trials

Trial Enrollment Status

Treatment Classifications

Phase